Definium Therapeutics NASDAQ: DFTX Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III data in major depressive disorder later this quarter and ongoing Phase III work in generalized anxiety disorder. Get Definium Therapeutics alerts: Roberts said Definium's Phase II GAD study evaluated 25-, 50-, 100- and 200-microgram doses and supported 100 micrograms as the go-forward dose. In the Phase III GAD ...